Stockscreener 앱 받기
1,080.36
0.53%
5.68
시간 외 거래:
1078.00
-2.36
-0.22%
전일 마감가:
$1,074.68
열려 있는:
$1076.4
하루 거래량:
2.45M
Relative Volume:
0.68
시가총액:
$966.94B
수익:
$59.42B
순이익/손실:
$18.41B
주가수익비율:
53.43
EPS:
20.2197
순현금흐름:
$6.44B
1주 성능:
+0.24%
1개월 성능:
+3.27%
6개월 성능:
+38.64%
1년 성능:
+38.85%
1일 변동 폭
$1,052.08
$1,080.66
1주일 범위
$1,052.08
$1,085.50
52주 변동 폭
$623.78
$1,111.99
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,080.36 | 961.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.35 | 498.60B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.31 | 403.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.54 | 264.54B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.45 | 261.26B | 63.90B | 19.05B | 13.05B | 7.5596 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Should FlyteHealth’s Employer Obesity Partnership Shape the GLP-1 Narrative for Eli Lilly (LLY) Investors? - Yahoo Finance UK
How Trump Moved Stocks In 2025: Crypto, Drones, Health Care Sectors - Benzinga
Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings - ts2.tech
Quattro Financial Advisors LLC Acquires New Position in Eli Lilly and Company $LLY - MarketBeat
Brown Miller Wealth Management LLC Buys 3,620 Shares of Eli Lilly and Company $LLY - MarketBeat
Bourgeon Capital Management LLC Purchases 10,676 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by Altfest L J & Co. Inc. - MarketBeat
Eli Lilly Shares Gain on Analyst Praise and Strategic Pricing Moves - AD HOC NEWS
Eli Lilly, Oracle, Home Depot, Canopy, Rocket Lab Insider Shake-Up - TipRanks
Sterling Investment Counsel LLC Buys 1,793 Shares of Eli Lilly and Company $LLY - MarketBeat
Silver Oak Securities Incorporated Has $3.32 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Mattern Capital Management LLC Buys 3,673 Shares of Eli Lilly and Company $LLY - MarketBeat
Financial Consulate Inc. Invests $938,000 in Eli Lilly and Company $LLY - MarketBeat
Ninety One UK Ltd Purchases 11,668 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly & Co.: How a 150-Year-Old Pharma Giant Became the World’s Hottest Growth Product - AD HOC NEWS
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Institutional Investors Signal Confidence in Eli Lilly Amidst Market Crosscurrents - AD HOC NEWS
What Makes Eli Lilly And Co. (LLY) a Worthy Holding? - Insider Monkey
RVW Wealth LLC Invests $910,000 in Eli Lilly and Company $LLY - MarketBeat
Miracle Mile Advisors LLC Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat
Celltrion completes acquisition of US Eli Lilly plant - theinvestor.co.kr
Burns J W & Co. Inc. NY Has $3.35 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Celltrion Acquires Eli Lilly’s U.S. Facility with 680 billion won CMO Contract - Businesskorea
The Truth About Eli Lilly and Company: Why Everyone Is Betting Big On This Pharma Giant - AD HOC NEWS
Celltrion completes acquisition of Eli Lilly manufacturing facility in New Jersey - koreabiomed.com
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites - ts2.tech
Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus - ts2.tech
Smith Salley Wealth Management Has $14.84 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Diversified Trust Co Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Ayrshire Capital Management LLC Has $7.42 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Strategic Gamble: Deep Price Cuts in China Challenge Profit Outlook - AD HOC NEWS
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026 - ts2.tech
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Could This Potential Move Boost Eli Lilly's Prospects? - AOL.com
Triangle biotech backed by Eli Lilly files to go public - The Business Journals
Segment Wealth Management LLC Buys 10,042 Shares of Eli Lilly and Company $LLY - MarketBeat
Simplify Asset Management Inc. Sells 4,453 Shares of Eli Lilly and Company $LLY - MarketBeat
Mirova US LLC Has $290.45 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Strategic Pivot: A Price War in China for Market Dominance - AD HOC NEWS
Eli Lilly Engages in Strategic Price Competition Amid Record Valuation - AD HOC NEWS
Eli Lilly-backed Insilico eyes beyond pharma with new AI models - Nikkei Asia
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight? - Benzinga
AI Company Raises 2.3 Billion Yuan for Listing with Eli Lilly and Temasek's Backing - 36Kr
The Truth About Eli Lilly and Company: Why Everyone on Wall Street Is Obsessed Right Now - AD HOC NEWS
Eli Lilly (LLY) Moves Fast to Secure Lead in India's Obesity Drug Market - Finviz
Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market - Insider Monkey
Novo and Lilly cut prices of weight-loss drugs in China - Reuters
Lilly Endowment Sells 3,593 Shares of Eli Lilly & Co - TradingView — Track All Markets
Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China - GuruFocus
Eli Lilly’s Strategic Price Cut Intensifies Rivalry in Chinese Weight-Loss Market - AD HOC NEWS
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China - Yahoo Finance UK
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
자본화:
|
볼륨(24시간):